Progress in understanding the pathogenesis of oculopharyngeal muscular dystrophy

Canadian Journal of Neurological Sciences

Volumn 30, Issue 1, 2003, Pages 8-14

  Fan, Xueping ^a   Rouleau, Guy A ^a,b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; MESSENGER RNA; NUCLEAR PROTEIN; POLYADENYLATED RNA; POLYALANINE; RIBONUCLEOPROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

AUTOSOMAL DOMINANT DISORDER; CLINICAL FEATURE; DYSPHAGIA; GENE MUTATION; HUMAN; MUSCLE DISEASE; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; ONSET AGE; PATHOGENESIS; PRIORITY JOURNAL; PTOSIS; REVIEW;

EID: 0037301515     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100002365     Document Type: Review

References (71)

1. Brais B, Xie YG, Sanson M, et al. The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2-q13. Hum Mol Genet 1995; 4: 429-434.
2. Brunet G, Tome FM, Samson F, et al. Dytrophie musculaire oculopharyngee. Recensement des familles francaises et etude genealogique. Rev Neurol 1990; 146: 425-429.
3. Brais B, Rouleau GA, Bouchard JP, et al. Oculopharyngeal muscular dystrophy. Semin Neurol 1999; 19: 59-66.
4. Tome FM, Fardeau M. Nuclear inclusions in oculopharyngeal dystrophy. Acta Neuropathologica 1980; 49: 85-87.
5. Pratt MF, Meyers PK. Oculopharyngeal muscular dystrophy: recent ultrastructural evidence for mitochondrial abnormalities. Laryngoscope 1986; 96: 368-373.
6. Tome FM, Askanas V, Engel WK, et al. Nuclear inclusions in innervated cultured muscle fibers from patients with oculopharyngeal muscular dystrophy. Neurol 1989; 39: 926-932.
7. Bouchard JP, Gagne F, Tome FM, Brunet D. Nuclear inclusions in oculopharyngeal muscular dystrophy in Quebec. Can J Neurol Sci 1989; 16: 446-450.
8. Coquet M, Vital C, Julien J. Presence of inclusion body myositis-like filaments in oculopharyngeal muscular dystrophy. Ultrastructural study of 10 cases. Neuropathol Appl Neurobiol 1990; 16: 393-400.
9. Blumen SC, Sadeh M, Korczyn AD, et al. Intranuclear inclusions in oculopharyngeal muscular dystrophy among Bukhara Jews. Neurol 1996; 46: 1324-1328.
10. Stajich JM, Gilchrist JM, Lennon F, et al. Confirmation of linkage of oculopharyngeal muscular dystrophy to chromosome 14q11.2q13 in American families suggests the existence of a second causal mutation. Neuromuscul Disord 1997; 7(Suppl 1): S75-S81.
11. Teh BT, Sullivan AA, Farnebo F, et al. Oculopharyngeal muscular dystrophy (OPMD)-report and genetic studies of an Australian kindred. Clin Genet 1997; 51: 52-55.
12. Porschke H, Kress W, Reichmann H, et al. Oculopharyngeal muscular dystrophy in a northern German family linked to chromosome 14q, and presenting carnitine deficiency. Neuromuscul Disord 1997; 7(Suppl 1): S57-S62.
13. Brais B, Bouchard JP, Xie YG, et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet 1998; 18: 164-167.
14. Wahle E. A novel poly(A)-binding protein acts as a specificity factor in the second phase of messenger RNA polyadenylation. Cell 1991; 66: 759-768.
15. Colgan DF, Manley JL. Mechanism and regulation of mRNA polyadenylation. Genes Dev 1997; 11: 2755-2766.
16. Minvielle-Sebastia L, Keller W. mRNA polyadenylation and its coupling to other RNA processing reactions and to transcription. Curr Opin Cell Biol 1999; 11: 352-357.
17. Barabino SML, Keller W. Last but not least: regulated poly(A) tail formation. Cell 1999; 99: 9-11.
18. Wahle E. Poly(A) tail length control is caused by termination of processive synthesis. J Biol Chem 1995; 270: 2800-2808.
19. Bienroth S, Keller W, Wahle E. Assembly of a processive messenger RNA polyadenylation complex. EMBO J 1993; 12: 585-594.
20. Wahle E, Lustig A, Jeno P, Maurer P. Mammalian poly(A)-binding protein II. Physical properties and binding to polynucleotides. J Biol Chem 1993; 268: 2937-2945.
21. Keller RW, Kuhn U, Aragon M, et al. The nuclear poly(A) binding protein, PABP2, forms an oligomeric particle covering the length of the poly(A) tail. J Mol Biol 2000; 297: 569-583.
22. Nemeth A, Krause S, Blank D, et al. Isolation of genomic and cDNA clones encoding bovine poly(A) binding protein II. Nuclei Acid Res 1995; 23: 4034-4041.
23. Temtamy SA, McKusick VA. Syndactyly as an isolated malformation. In: The Genetics of Hand Malformations. Birth Defects: Original Article Series vol. XIV (3). Alan RL. New York, 1978; 301-322.
24. Muragaki Y, Mundlos S, Upton J, Olsen BR. Altered growth and branching patterns in synpolydactyly caused by mutations in HOXD13. Science 1996; 272: 548-551.
25. Izpisua-Belmonte JC, Duboule D. Homeobox genes and pattern formation in the vertebrate limb. Dev Biol 1992; 152: 26-36.
26. Goodman FR, Mundlos S, Muragaki Y, et al. Synpolydactyly phenotypes correlated with size of expansions in HOXD13 polyalanine tract. Proc Natl Acad Sci USA 1997; 94: 7458-7463.
27. Mundlos S, Otto F, Mundlos C, et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 1997; 89: 773-779.
28. Jones KL. Smith's Recognizable Patterns of Human Malformation, 5th ed. 1997 Philadelphia: W.B. Saunders Company.
29. Mundlos S, Olsen BR. Heritable diseases of the skeleton. Part I: molecular insights into skeletal development-transcription factors and signaling pathways. FASEB J 1997; 11: 125-132.
30. Mundlos S, Olsen BR. Heritable diseases of the skeleton. Part II: molecular insights into skeletal development-matrix components and their homeostasis. FASEB J 1997; 11: 227-233.
31. Otto F, Thornell AP, Crompton T, et al. Cbfa1, a candidate gene for Cleidocranial Dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997; 89: 765-771.
32. Nanni L, Croen LA, Lammer EJ, Muenke M. Holoprosencephaly: molecular study of a California population. Am J Med Genet 2000; 90: 315-319.
33. Brown SA, Warburton D, Brown LY, et al. Holoprosencephaly due to mutations in ZIC2, a homologue of Drosophila odd-paired. Nat Genet 1998; 20: 180-183.
34. Nagai T, Aruga J, Takada S, et al. The expressions of the mouse Zic1, Zic2, and Zic3 genes suggest an essential role for Zic genes in body pattern formation. Dev Biol 1997; 182: 299-313.
35. Halal F. The hand-foot-genital (hand-foot-uterus) syndrome: family report and update. Am J Med Genet 1988; 30: 793-803.
36. Goodman FR, Bacchelli C, Brady AF, et al. Novel HOXA13 mutations and the phenotypic spectrum of hand-foot-genital syndrome. Am J Hum Genet 2000; 67: 197-202.
37. Crisponi L, Deiana M, Loi A, et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet 2001; 27: 159-166.
38. Zlotogora J, Sagi M, Cohen T. The blepharophimosis, ptosis, and epicanthus inversus syndrome: delineation of two types. Am J Hum Genet 1983; 35: 1020-1027.
39. Prueitt RL, Zinn AR. A fork in the road to fertility. Nat Genet 2001; 27: 132-134.
40. Rankin J, Wyttenbach A, Rubinsztein DC. Intracellular green fluorescent protein-polyalanine aggregates are associated with cell death. Biochem J 2000; 348: 15-19.
41. Gaspar C, Jannatipour M, Dion P, et al. CAG tract of MJD-1 may be prone to frameshifts causing polyalanine accumulation. Hum Mol Genet 2000; 9: 1957-1966.
42. Blondelle SE, Forood B, Houghten RA, Perez-Paya E. Polyalanine-based peptides as models for self-associated beta-pleated-sheet complexes. Biochem 1997; 36: 8393-8400.
43. Forood B, Perez-Paya E, Houghten RA, Blondelle SE. Formation of an extremely stable polyalanine beta-sheet macromolecule. Biochem Biophys Res Commun 1995; 211: 7-13.
44. Calado A, Tome FMS, Brais B, et al. Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA. Hum Mol Genet 2000; 9: 2321-2328.
45. Shanmugam V, Dion P, Rochefort D, et al. PABP2 polyalanine tract expansion causes intranuclear inclusions in oculopharyngeal muscular dystrophy. Ann Neurol 2000; 48: 798-802.
46. Kim YJ, Noguchi S, Hayashi YK, et al. The product of an oculopharyngeal muscular dystrophy gene, poly(A)-binding protein 2, interacts with SKIP and stimulates muscle-specific gene expression. Hum Mol Genet 2001; 10: 1129-1139.
47. Fan X, Dion P, Laganiere J, et al. Oligomerization of polyalanine expanded PABPN1 facilitates nuclear protein aggregation that is associated with cell death. Hum Mol Genet 2001; 10: 2341-2351.
48. Ferrigno P, Silver PA. Polyglutamine expansions: proteolysis, chaperones, and the dangers of promiscuity. Neuron 2000; 26: 9-12.
49. Sherman MY, Goldberg AL. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 2001; 29: 15-32.
50. Bates GP, Mangiarini L, Davies SW. Transgenic mice in the study of polyglutamine repeat expansion diseases. Brain Pathol 1998; 8: 699-714.
51. Yong A. Huntington's Disease and Other Trinucleotide Repeat Disorders. Martin J, Eds. New York: Scientific American, Inc. 1998.
52. Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998; 95: 55-66.
53. Klement IA, Skinner PJ, Kaytor MD, et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 1998; 95: 41-53.
54. Bao YP, Cook LJ, O'Donovan D, et al. Mammalian, yeast, bacterial, and chemical chaperones reduce aggregate formation and death in a cell model of oculopharyngeal muscular dystrophy. J Biol Chem 2002; 277: 12263-12269.
55. Evert BO, Wullner U, Schulz JB, et al. High level expression of expanded full-length ataxin-3 in vitro causes cell death and formation of intranuclear inclusions in neuronal cells. Hum Mol Genet 1999; 8: 1169-1176.
56. Turmaine M, Raza A, Mahal A, et al. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci USA 2000; 97: 8089-8097.
57. Wahle E, Kuhn U. The mechanism of 3' cleavage and polyadenylation of eukaryotic pre-mRNA. Prog Nucleic Acid Res Mol Biol 1997; 57: 41-71.
58. Chen Z, Li Y, Krug R. Influenza A virus NS1 protein targets poly(A)-binding protein II of the cellular 3'-end processing machinery. EMBO J 1999; 18: 2273-2283.
59. Calado A, Kutay U, Kuhn U, et al. Deciphering the cellular pathway for transport of poly(A)-binding protein II. RNA 2000; 6: 245-256.
60. Dreyfuss G, Matunis MJ, Pino-Roma S, Burd CG. hnRNP proteins and the biogenesis of mRNA. Ann Rev Biochem 1993; 62: 289-321.
61. Swanson MS. Functions of nuclear pre-mRNA/mRNA binding proteins. In: Lamond AI, Eds. Pre-mRNA Processing. Berlin/New York: Springer Verlag, 1995: 17-33.
62. Pinol-Roma S, Dreyfuss G. Shuttling of pre-mRNA binding proteins between nucleus and cytoplasm. Nature 1992; 355: 730-732.
63. Visa N, Alzhanova-Ericsson AT, Sun X, Kiseleva E. A pre-mRNA-binding protein accompanies the RNA from the gene through the nuclear pores and into polysomes. Cell 1996; 84: 253-264.
64. Nakielny S, Dreyfuss G. Nuclear export of proteins and RNAs. Curr Opin Cell Biol 1997; 9: 420-429.
65. Krecic AM, Swanson MS. hnRNP complexes: composition, structure, and function. Curr Opin Cell Biol 1999; 11: 363-371.
66. Kumar A, Sierakowska H, Szer W. Purification and RNA binding properties of a C-type hnRNP protein from HeLa cells. J Biol Chem 1987; 262: 17126-17137.
67. Khan FA, Jaiswal AK, Szer W. Cloning and sequence analysis of a human type A/B hnRNP protein. FEBS 1991; 290: 159-161.
68. Lau PP, Zhu HJ, Nakamuta M, Chan L. Cloning of an apobec-1-binding protein that also interacts with apolipoprotein B mRNA and evidence for its involvement in RNA editing. J Biol Chem 1997; 272: 1452-1455.
69. Innerarity TL, Boren J, Yamanaka S, Olofsson SO. Biosynthesis of apolipoprotein B48-containing lipoproteins. J Biol Chem 1996; 271: 2353-2356.
70. Lau PP, Xiong W, Zhu HJ, et al. Apolipoprotein B mRNA editing is an intranuclear event that occurs posttranscriptionally coincident with splicing and polyadenylation. J Biol Chem 1991; 266: 20550-20554.
71. Dahl R, Wani B, Hayman MJ. The Ski oncoprotein interacts with Skip, the human homolog of Drosopila Bx42. Oncogene 1998; 16: 1579-1586.